96 results about "Lung Inflammations" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of a nauclea officinalis extract in preparation of a medicine for treating chronic obstructive pulmonary diseases. Experimental research shows that the nauclea officinalis extract is used for treating the chronic obstructive pulmonary disease, can inhibit lung inflammation of a patient suffering from the chronic obstructive pulmonary disease and improve the lung function and emphysema injury of the chronic obstructive pulmonary disease, can be used for preventing and treating the chronic obstructive pulmonary disease, and can be used for preventing and treating the chronic obstructive pulmonary disease. And a new strategy is provided for the development of medicines for treating chronic obstructive pulmonary diseases.

The invention discloses cubilose sialic acid glycan peptide capable of improving lung inflammation and application of the cubilose sialic acid glycan peptide. The ratio of fucose modified sugar chains in the cubilose sialic acid glycan peptide is 30-60%, the ratio of sialic acid modified sugar chains in the cubilose sialic acid glycan peptide is 20-40%, the core structure of the fucose type is (HexNAc) 3 (Man) 3 (Fuc) 1, the core structure of the sialic acid type is (HexNAc) 3 (Man) 3 (Gal) 1 (Fuc) 1 (NeuAc) 1, the neutral sugar dissolution rate of the cubilose sialic acid glycan peptide is high, and the glycopeptide shown in SEQ ID NO 2 has a good inflammation improving effect.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The invention discloses application of a cytisine type alkaloid and a derivative thereof in preparation of a medicine for preventing or treating respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The research finds that the natural product cytisine shows good anti-respiratory syncytial virus infection activity in vivo and in vitro, and finds that the cytisine can obviously relieve lung injury caused by virus infection and reduce lung inflammation; the invention provides an experimental basis for developing an efficient and safe drug for resisting respiratory syncytial virus (RSV) infection. As a natural product, the cytisine reduces the social burden caused by treatment of respiratory syncytial virus infection and reduces the treatment cost.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

This invention discloses the application of 2,4-di-tert-butylphenol in the preparation of anti-human respiratory syncytial virus (RSV) drugs, belonging to the field of biomedical technology. 2,4-Di-tert-butylphenol exhibits good anti-RSV effects both in vitro and in vivo. In vitro, it can inhibit viral infection of cells, and in vivo, it can alleviate lung damage caused by viral infection and reduce lung inflammation. This invention provides experimental evidence for the development of highly effective and safe anti-RSV drugs and also offers more drug options for their development.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 strain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and / or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The invention relates to the technical field of biological medicines, in particular to application of a CD20 inhibitor in treatment of chronic obstructive pulmonary diseases. The CD20 inhibitor can remarkably improve emphysema and small airway collagen deposition in chronic obstructive pulmonary diseases, inhibit expression of inflammatory factors IL-6 and TNF-alpha in lung tissue, reduce the concentration of chemotactic factors CXCL2 in bronchoalveolar lavage fluid and relieve lung inflammation, and the treatment effect is remarkable. Obviously, CD20 can become a potential clinical treatment target of chronic obstructive pulmonary disease.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention discloses an exosome atomized preparation as well as a preparation method and application thereof, and belongs to the technical field of exosome technology and respiratory disease treatment. The problems that antibiotics and anti-inflammatory drugs adopted in the prior art have the defects of drug resistance, large side effects and the like in lung inflammation are solved. The exosome is derived from stem cells which are subjected to gp96 pretreatment and overexpress gp96 antigen information, the gp96 activates antigen presenting cells, the delivery efficiency of immunomodulatory factors (such as IL-10 and TGF-beta) carried by the exosome is enhanced, proinflammatory factors (such as TNF-alpha and IL-6) are inhibited, and in combination with the administration mode of an atomized preparation, through aerosol inhalation, the exosome can be used for preparing the immunomodulatory factor immunomodulatory agent. The exosome can directly reach a lung lesion area, so that the local drug concentration is improved, and the systemic side effects are reduced.

The invention discloses an application of an exosome carrying miR-486 in pulmonary interstitial fibrosis, and belongs to the technical field of biological medicines, and the exosome carrying miR-486 is an exosome carrying miR-486 from umbilical cord stem cells; according to the application disclosed by the invention, the umbilical cord stem cell-derived exosome carrying the miR-486 is used for treating the pulmonary interstitial fibrosis for the first time, and the action mechanism of the umbilical cord stem cell-derived exosome carrying the miR-486 is that the umbilical cord stem cell-derived exosome carrying the miR-486 regulates fibroblast MRC-5 cell differentiation and collagen deposition through targeting FGF9; the development process of pulmonary interstitial fibrosis is improved and delayed by improving lung inflammation of mice with pulmonary interstitial fibrosis caused by bleomycin, reducing collagenous fiber deposition, inflammatory response, ECM process and pulmonary vascular structure reconstruction, and a new way is provided for treatment of the disease.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

The invention relates to a system for measuring a level of a subject's immune activity (10), the system comprising: - an exhaled air sensor (20), - a device for measuring exhaled air (30), - computation means (40) suitable for determining data relating to the air exhaled by the subject from the measurements carried out by the device (30), - a memory (60) suitable for storing the measurements performed by the device (30) and / or the data calculated by the means (40), and the subject's personal data, - a computation means (70) suitable for determining a level of the subject's immune activity on the basis of at least one item of exhaled air data, generated in real time by the means (40) and / or stored in the memory (60), - a communication and management interface (80) suitable for presenting said level of the subject's immune activity and / or sub-scores of immunological activity, inflammatory activity, digestive inflammation and / or pulmonary inflammation.

To provide a pharmaceutical composition for treating lung inflammation in a mammalian subject having a granulomatous pulmonary disease.SOLUTION: A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a GHRH antagonist.SELECTED DRAWING: None

The present invention relates to a pharmaceutical combination comprising a first active ingredient, which is a CXCR3 antagonist 1-{(R)-2-(2-hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1, 2, 4] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] triazole-5-yl)-2-(3-methyl-[1, 2, 3] a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)) and a second active ingredient (which is an anti-CD3 monoclonal antibody (mAb)); the invention also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease, and the like), and also relates to the application of the medicine combination in the prevention / prevention and / or treatment of (autoimmune) / inflammation-mediated conditions (including type 1 diabetes mellitus (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially kidney and heart allograft rejection), thyroid eye diseases, rheumatoid arthritis, ulcerative colitis, Crohn's disease, celiac disease and the like. The traditional Chinese medicine composition can be used for treating psoriasis, atherosclerosis, psoriasis, lung inflammation and psoriatic arthritis

In some aspects, provided herein are compositions of and methods for utilizing a sterically stabilized liposome carrier encapsulating a selected drug for the delivery of such drug effectual in the treatment of a mammal infected by a virus, such as SARS-COV-2, specifically in inhibiting the viral replication and reducing symptoms including lung inflammation. The compositions and methods disclosed herein provide a potential treatment for COVID-19 with improved patient compliance as they offer a less frequent dosing for the “long haulers” post COVID-19 initial infection.

Use of an E-TMED10 inhibitor in preparing a product for treating and / or preventing inflammation. The interaction between the E protein of the coronavirus and the TMED10 (E-TMED10) is a potential molecular mechanism for driving excessive inflammation induced by the coronavirus, and is also a potential treatment target for resisting inflammation harmful effects induced by the coronavirus. The interaction between the E protein of the coronavirus and the TMED10 is blocked or reduced, such that the release of pro-inflammatory factors can be reduced, thereby reducing lung inflammation.

The invention provides a pollen vaccine based on an aluminum-CpG composite adjuvant and application of the pollen vaccine. The pollen vaccine comprises an aluminum-CpG chemical coupling nano adjuvant and a recombinant mugwort main allergen, the adjuvant is a substance formed by coupling an aluminum oxygen hydride nanorod and CpG through an amido bond, carboxyl on the surface of an AlOOH nanorod is activated, and then the AlOOH nanorod reacts with aminated CpG ODN to obtain the adjuvant. Stable combination of the aluminum salt nanoparticles and CpG ODN is achieved through chemical coupling, the coupling efficiency is larger than or equal to 95%, cytotoxicity is avoided, the problems that in traditional physical mixing, the aluminum salt nanoparticles and CpG ODN are not synergistic in effect and prone to dissociation are solved, and the synergistic immunoregulation effect of adjuvant components is ensured; after the adjuvant is loaded with the Artemisia pollen allergen Art v1, the IgE level can be remarkably reduced, lung inflammation can be relieved, allergic symptoms can be improved in treatment and prevention models, and a novel adjuvant platform is provided for immunotherapy of pollen allergy.

The invention provides a spanishneedles herb exosome as well as a preparation method and application thereof in acute lung injury, and belongs to the technical field of biological medicines. According to the preparation method of the spanishneedles herb exosome provided by the invention, the spanishneedles herb exosome can be extracted from a plant source through a simple method. In one embodiment of the invention, a lung injury model constructed by using LPS is used as an experimental animal to verify the therapeutic effect of the spanishneedles herb exosome. Results show that after the spanishneedles herb exosome is used for treatment, mouse lung tissue injury and inflammatory cell exudation can be relieved, and lung injury caused by LPS can be relieved; tNF-alpha and IL-1beta in lung lavage fluid of a mouse are remarkably reduced, and lung inflammation infiltration of the mouse can be relieved. Therefore, the spanishneedles herb exosome has the effect of treating the acute lung injury and can be used for preparing the medicine for treating the acute lung injury.

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

The invention provides a ganoderma lucidum molecular ecological liquid extract obtained through specific fermentation and a preparation method and application thereof, and belongs to the technical field of microbial fermentation. According to the method, an improved fermentation culture medium is adopted, 5-8% of CO2 is introduced, fermentation is performed for 90-180 days at the temperature of 30-32 DEG C under the condition that the concentration of dissolved oxygen in the environment is kept to be 20-30%, and after purification, the extract of the ganoderma lucidum molecular ecological liquid is obtained. According to the myxomycete molecular ecological liquid prepared by the preparation method provided by the invention, the content of active ingredients for relieving the symptoms of the chronic obstructive pulmonary disease can be remarkably increased; moreover, an in-vitro cell experiment verifies that the extract of the ganoderma lucidum molecular ecological liquid has an inhibition effect on an A549 cell line, and an animal experiment further proves that the extract of the ecological liquid can regulate and control the expression level of proinflammatory cytokines, so that lung inflammation is inhibited, pathological injury of lung tissues is relieved, and local abnormal conditions of the lung are improved.

The invention relates to the technical field of nano-drugs, in particular to a glucocorticoid nano-emulsion, a liposome, a freeze-drying preparation and application of the glucocorticoid nano-emulsion, the liposome and the freeze-drying preparation in treatment of acute lung injury. According to the glucocorticoid nano-emulsion and lipidosome, accumulation of a nano-preparation in an inflammation part can be effectively increased through SA modification, selective targeting of the nano-preparation on the inflammation part is achieved, acute lung inflammation of ALI mice is remarkably relieved through pulmonary drug delivery, and under the same dosage, compared with lipidosome, the dosage of the nano-emulsion and lipidosome is reduced, and the dosage of the nano-emulsion and lipidosome is reduced. The nano-emulsion shows the best anti-inflammatory treatment effect. The nano preparation provided by the invention is good in biological safety and has a wide development prospect.

The invention discloses an application of arbutin in preparation of a medicine for preventing or treating pneumonia injury. Experimental results show that after being dosed in an intraperitoneal injection form, the arbutin regulates an autophagy pathway mediated by a molecular chaperone and inhibits degradation of oxidative stress negative regulatory factor PRL2 protein, so that generation and release of neutrophil extracellular traps are reduced, lung inflammatory response and tissue damage are relieved, and the curative effect of the arbutin is improved. The traditional Chinese medicine composition has a good improvement effect on pneumonia injury mice. The application provides important theoretical basis and experimental basis for prevention or treatment of pneumonia injury, further provides scientific basis for clinical medication for guiding treatment of pneumonia injury, and has good application prospect.

Part of this invention provides novel small molecule PHD inhibitors having structures according to formula (I) and its derivatives: or pharmaceutically acceptable salts thereof. The compounds provided herein may be used to treat the following diseases: including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory diseases (e.g., respiratory infections, acute respiratory distress syndrome), liver diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute kidney injury and chronic kidney disease), inflammatory bowel disease (IBD), ischemic-reperfusion injury (e.g., stroke), and retinopathy of prematurity (ROP).

The present invention discloses the use of an alkaloid in the preparation of a drug for anti-neuroinflammation and improving lung injury. The use is the use of Cottoquinazoline B in the preparation of a drug for preventing and / or treating neurodegenerative diseases caused by neuroinflammation, or the use is the use of Cottoquinazoline B in the preparation of a drug for preventing and / or treating lung injury caused by pulmonary inflammation. The present invention discovers that the compound Cottoquinazoline B derived from the marine-derived fungus Aspergillus niger can significantly reduce the lipopolysaccharide-induced neuroinflammatory response, can significantly alleviate the lipopolysaccharide-induced pulmonary inflammatory response, and can reduce the lipopolysaccharide-induced serum cytokine level, and has good application prospects and commercial value.